Literature DB >> 8956687

Treating breast cancer before surgery.

R Epstein.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8956687      PMCID： PMC2352900          DOI： 10.1136/bmj.313.7069.1345

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

Authors:  O Stål; S Sullivan; S Wingren; L Skoog; L E Rutqvist; J M Carstensen; B Nordenskjöld
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

2.  I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894.

Authors:  W S Halsted
Journal:  Ann Surg       Date:  1894-11       Impact factor: 12.969

3.  Specialist surgeons and survival in breast cancer. Large differences in survival are not explained.

Authors:  M Baum
Journal:  BMJ       Date:  1996-05-04

4.  Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.

Authors:  M D Abeloff; R A Beveridge; R C Donehower; J H Fetting; N E Davidson; G G Gordon; W C Waterfield; D J Damron
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

5.  Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

Authors:  R M Elledge; R Gray; E Mansour; Y Yu; G M Clark; P Ravdin; C K Osborne; K Gilchrist; N E Davidson; N Robert
Journal:  J Natl Cancer Inst       Date:  1995-08-16       Impact factor: 13.506

6.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

7.  Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

Authors:  B Fisher; J Dignam; E P Mamounas; J P Costantino; D L Wickerham; C Redmond; N Wolmark; N V Dimitrov; D M Bowman; A G Glass; J N Atkins; N Abramson; C M Sutherland; B S Aron; R G Margolese
Journal:  J Clin Oncol       Date:  1996-07       Impact factor: 44.544

8.  Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland.

Authors:  C R Gillis; D J Hole
Journal:  BMJ       Date:  1996-01-20

9.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.

Authors:  A F Wahl; K L Donaldson; C Fairchild; F Y Lee; S A Foster; G W Demers; D A Galloway
Journal:  Nat Med       Date:  1996-01       Impact factor: 53.440

10.  Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

Authors:  T J Powles; T F Hickish; A Makris; S E Ashley; M E O'Brien; V A Tidy; S Casey; A G Nash; N Sacks; D Cosgrove
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.